About US
Contact us
-
AbbVie's Humira defense may keep prices high, but it's still legal, judge rulesAbbViereaps billions of dollars annually fromits big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drugis likely free from U.S. competition until 2023.A classof pur2020/6/10
-
FDA official leaves 'Warp Speed' to preserve independent regulatory power: reportWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect drug pricing and how drugmakers operate. As rese2020/6/9
-
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?Six years ago, AstraZeneca CEO Pascal Soriot fought off Pfizer’s $118 billion takeover attempt. Now, the defender is reportedly playing offense, going after a deal of similar size. The British pharma2020/6/9
-
'Onshoring' drug manufacturing; Takeda's IBD pipeline cull; Legend's $350M IPOThe pharma industry is pushing backat the government's call to "onshore" manufacturing for the U.S. market.Takeda decided to stop development of Shire's SHP647, a drug the European Commission had ask2020/6/8
-
Study suggests hydroxychloroquine doesn't prevent COVID-19. But questions remainPresident Donald Trump said in May that he was taking hydroxychloroquine to guard against COVID-19 infection. But does the anti-malaria drugwork as preventive measure for the novel coronavirus? It do2020/6/8
-
Novartis' Cosentyx chases Lilly's just-approved Taltz with long-term data in spondyloarthritisNovartis' Cosentyx lost a race against Eli Lilly's Taltz after the latter scored an FDA approval in spondyloarthritis earlier this week. But Cosentyx, which facesan FDA review in that indication, is2020/6/5
-
FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumabLast week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which w2020/6/4
-
IMCD appoints new Managing Director in ChinaShanghai, China (June 3rd 2020) –IMCD China, partof the IMCD Group, a global leading distributor of speciality chemicals andfood ingredients, has appointed Andreas Igerl, as Managing Director,effecti2020/6/3
-
Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?AstraZeneca’s CTLA4 candidate tremelimumab has suffered a host of clinical failures that have so far kept it off the market. But new phase 2 results show the company might just be able to use the dru2020/6/2
-
Trump trade adviser, citing 'broken system,' calls for more drug manufacturing in Puerto RicoWelcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. The COVID-12020/6/2